EX-10.10





 Exhibit 10.10 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed. 
 PREFERRED STOCK PURCHASE AGREEMENT 

GABA THERAPEUTICS, INC. 













							
	 	  	 	  	 	  	 Page

			
	1.	  	Purchase and Sale of Preferred Stock	  	1
				
		  	1.1	  	Sale and Issuance of Preferred Stock	  	1
		  	1.2	  	Closing; Delivery	  	1
		  	1.3	  	Sale of Milestone Shares	  	1
		  	1.4	  	Use of Proceeds	  	2
		  	1.5	  	Defined Terms Used in this Agreement	  	2
			
	2.	  	Representations and Warranties of the Company	  	4
				
		  	2.1	  	Organization, Good Standing, Corporate Power and Qualification	  	4
		  	2.2	  	Capitalization	  	4
		  	2.3	  	Subsidiaries	  	5
		  	2.4	  	Authorization	  	5
		  	2.5	  	Valid Issuance of Shares	  	5
		  	2.6	  	Governmental Consents and Filings	  	6
		  	2.7	  	Litigation	  	6
		  	2.8	  	Intellectual Property	  	6
		  	2.9	  	Compliance with Other Instruments	  	7
		  	2.10	  	Agreements; Actions	  	8
		  	2.11	  	Certain Transactions	  	8
		  	2.12	  	Rights of Registration and Voting Rights	  	9
		  	2.13	  	Property	  	9
		  	2.14	  	Material Liabilities	  	9
		  	2.15	  	Employee Matters	  	9
		  	2.16	  	Tax Returns and Payments	  	11
		  	2.17	  	Insurance	  	11
		  	2.18	  	Employee Agreements	  	11
		  	2.19	  	Permits	  	11
		  	2.20	  	Corporate Documents	  	11
		  	2.21	  	Qualified Small Business Stock	  	12
		  	2.22	  	Disclosure	  	12
		  	2.23	  	Foreign Corrupt Practices Act	  	12
		  	2.24	  	Preclinical Development	  	13
			
	3.	  	Representations and Warranties of the Purchaser	  	13
				
		  	3.1	  	Authorization	  	13
		  	3.2	  	Purchase Entirely for Own Account	  	13
		  	3.3	  	Disclosure of Information	  	13
		  	3.4	  	Restricted Securities	  	14
		  	3.5	  	No Public Market	  	14
		  	3.6	  	Legends	  	14
		  	3.7	  	Accredited Investor	  	14
		  	3.8	  	Foreign Investors	  	15


  
 i 














							
		  	3.9	  	No General Solicitation	  	15
		  	3.10	  	Exculpation Among Purchaser	  	15
		  	3.11	  	Residence	  	15
			
	4.	  	Conditions to the Purchaser’s Obligations at each Closing	  	15
				
		  	4.1	  	Representations and Warranties	  	15
		  	4.2	  	Performance	  	15
		  	4.3	  	Compliance Certificate	  	15
		  	4.4	  	Qualifications	  	15
		  	4.5	  	Opinion of Company Counsel	  	16
		  	4.6	  	Indemnification Agreement	  	16
		  	4.7	  	Investors’ Rights Agreement	  	16
		  	4.8	  	Right of First Refusal and Co-Sale Agreement	  	16
		  	4.9	  	Voting Agreement	  	16
		  	4.10	  	Employment Agreement	  	16
		  	4.11	  	Restated Certificate	  	16
		  	4.12	  	D&O Insurance	  	16
		  	4.13	  	Secretary’s Certificate	  	16
		  	4.14	  	Proceedings and Documents	  	16
		  	4.15	  	Post-Closing Covenants	  	17
			
	5.	  	Conditions of the Company’s Obligations at each Closing	  	17
				
		  	5.1	  	Representations and Warranties	  	17
		  	5.2	  	Performance	  	17
		  	5.3	  	Qualifications	  	17
			
	6.	  	Miscellaneous	  	17
				
		  	6.1	  	Survival of Warranties	  	17
		  	6.2	  	Successors and Assigns	  	17
		  	6.3	  	Governing Law	  	17
		  	6.4	  	Counterparts	  	18
		  	6.5	  	Titles and Subtitles	  	18
		  	6.6	  	Notices	  	18
		  	6.7	  	No Finder’s Fees	  	18
		  	6.8	  	Fees and Expenses	  	18
		  	6.9	  	Attorneys’ Fees	  	18
		  	6.10	  	Amendments and Waivers	  	18
		  	6.11	  	Severability	  	19
		  	6.12	  	Delays or Omissions	  	19
		  	6.13	  	Entire Agreement	  	19
		  	6.14	  	Termination of Closing Obligations	  	19
		  	6.15	  	Dispute Resolution	  	20
		  	6.16	  	No Commitment for Additional Financing	  	20
		  	6.17	  	No Further Issuances	  	21


  
 ii 













 PREFERRED STOCK PURCHASE AGREEMENT 

THIS PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 29th day of August 2019 by and between GABA
THERAPEUTICS, INC., a Delaware corporation (the “Company”), and ATAI Life Sciences AG, a German stock corporation or an affiliate thereof (“ATAI” or “Purchaser”). 

The parties hereby agree as follows: 

1. Purchase and Sale of Preferred Stock. 

1.1 Sale and Issuance of Preferred Stock. 

(a) The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Initial Closing (as defined below)
the Amended and Restated Certificate of Incorporation in the form of EXHIBIT B attached to this Agreement (the “Restated Certificate”). 

(b) Subject to the terms and conditions of this Agreement, the Purchaser agrees to purchase at the Closing and the Company agrees to sell and
issue to the Purchaser at the Closing that number of shares of Series A Preferred Stock, $0.01 par value per share (the “Series A Preferred Stock”), set forth opposite the Purchaser’s name on Exhibit A, at a purchase
price of $[***] per share (the “Purchase Price”). The shares of Series A Preferred Stock issued to the Purchasers pursuant to this Agreement (including any shares issued at the Initial Closing and any Milestone Shares, as defined
below) shall be referred to in this Agreement as the “Shares.” 
 1.2 Closing; Delivery. 

(a) The initial purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures, on or about 1 p.m.
PST, on August 29, 2019, or at such other time and place as the Company and the Purchaser mutually agree upon, orally or in writing (which time and place are designated as the “Initial Closing” and together with any Milestone
Closing (as defined in Section 1.3(b) below), each a “Closing”). 
 (b) At each Closing, the Company shall deliver to
the Purchaser a certificate representing the Shares being purchased by the Purchaser at such Closing against payment of the purchase price therefor by wire transfer to a bank account designated by the Company. 

1.3 Sale of Milestone Shares. 

(a) After the Initial Closing, the Company shall sell, and the Purchasers shall purchase, on the same terms and conditions as those contained
in this Agreement: 
 (i) [***] shares of Series A Preferred Stock $0.01 par value per share at the Purchase Price on the
certification by the Board that the events specified under “Milestone 1” in Exhibit I attached to this Agreement have occurred (“Milestone 1”); and 

  
 1 













 (ii) Up to such number of shares determined by the Board (up to a maximum
of $[***] worth of Series A Preferred Stock $0.01 par value per share) at the Purchase Price no later than thirty (30) days following receipt of the certification by the Board that the events specified under “Milestone 2” in
Exhibit I attached to this Agreement have occurred (“Milestone 2” and together with Milestone 1, the “Milestones”); provided, however, that the Purchaser shall have the right, but not the
obligation, to purchase the Milestone Shares at any time upon notice to the Company, prior to the achievement of any Milestone. 
 (b) The
date of the purchase and sale of the Milestone Shares are referred to in this Agreement as the “Milestone Closing.” 
 (c)
Exhibit A to this Agreement shall be updated to reflect the number of Milestone Shares purchased at each such Milestone Closing. 

1.4 Use of Proceeds. In accordance with the directions of the Company’s Board of Directors, as it shall be constituted in
accordance with the Voting Agreement, the Company will use the proceeds from the sale of the Shares for activities in connection with the Company’s clinical development plan to achieve the Milestones and, as set forth on Exhibit B, to conduct
related pre-clinical studies to submit an Investigational New Drug (“IND”) application for the Company’s lead product candidates to the U.S. Food and Drug Administration
(“FDA”), and an amount of up to $100,000 to undertake such preparatory activities as may be required in connection with an initial public offering (“IPO”). Further IPO-
related expenses need to be approved by the Board of Directors. 
 1.5 Defined Terms Used in this Agreement. In addition to the terms
defined above or otherwise in this Agreement, the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below. 

(a) “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or
hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. 

(b) “Code” means the Internal Revenue Code of 1986, as amended. 

(c) “Company Intellectual Property” means all patents, patent disclosures and all related continuations, continuations-in-part, divisional, reissues, reexamination, utility models, renewals, extensions, certificates of invention and design patents, patent applications,
registrations and applications for registrations; registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information
and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases
that are owned or used by the Company in the conduct of the Company’s business as now conducted and as presently proposed to be conducted. 

  
 2 













 (d) “Founder” means GABA Therapeutics LLC. 

(e) “Founder Member” means each of Ian J. Massey, Richard G. Farrell, David G. Putman, and Oliver Dasse. 

(f) “Indemnification Agreement” means the agreement between the Company and the director and Purchaser Affiliates designated
by the Purchaser entitled to designate a member of the Board of Directors pursuant to the Voting Agreement, dated as of the date of the Initial Closing, in the form of EXHIBIT D attached to this Agreement. 

(g) “Investors’ Rights Agreement” means the agreement among the Company and the Purchasers and certain other
stockholders of the Company dated as of the date of the Initial Closing, in the form of EXHIBIT E attached to this Agreement. 
 (h)
“Knowledge” including the phrase “to the Company’s knowledge” shall mean the actual knowledge after reasonable inquiry of any Ian J. Massey and Richard G. Farrell. 

(i) “Material Adverse Effect” means a material adverse effect on the business, assets (including intangible assets),
liabilities, financial condition, property, or results of operations of the Company. 
 (j) “Person” means any individual,
corporation, partnership, trust, limited liability company, association or other entity. 
 (k) “Right of First Refusal and Co-Sale Agreement” means the agreement among the Company, the Purchaser, and certain other stockholders of the Company, dated as of the date of the Initial Closing, in the form of Exhibit F attached
to this Agreement. 
 (l) “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 (m) “Shares” means the shares of Series A Preferred Stock issued at the Initial Closing and any
Milestone Shares issued at a subsequent Closing under Subsection 1.2(b). 
 (n) “Transaction Agreements” means this
Agreement, the Investors’ Rights Agreement, the Right of First Refusal and Co-Sale Agreement and the Voting Agreement. 

(o) “Voting Agreement” means the agreement among the Company, the Purchaser and certain other stockholders of the Company,
dated as of the date of the Initial Closing, in the form of EXHIBIT G attached to this Agreement. 

  
 3 













 2. Representations and Warranties of the Company. The Company hereby represents and
warrants to the Purchaser that, except as set forth on the Disclosure Schedule attached as Exhibit C to this Agreement, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations
are true and complete as of the date of the Initial Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections and subsections contained in this Section 2,
and the disclosures in any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this Section 2 only to the extent it is readily apparent from a reading of the disclosure that such disclosure is
applicable to such other sections and subsections. 
 2.1 Organization, Good Standing, Corporate Power and Qualification. The Company
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted.
The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect. 

2.2 Capitalization. 
 (a)
The authorized capital of the Company consists, immediately prior to the Initial Closing, of: 
 (i) [***] shares of common
stock, $0.01 par value per share (the “Common Stock”), [***] shares of which are issued and outstanding immediately prior to the Initial Closing. All of the outstanding shares of Common Stock have been duly authorized, are fully
paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. The Company holds no Common Stock in its treasury. 

(ii) 20,000,000 shares of Preferred Stock, of which 20,000,000 shares have been designated Series A Preferred Stock; none of
which are issued and outstanding immediately prior to the Initial Closing. The rights, privileges and preferences of the Preferred Stock are as stated in the Restated Certificate and as provided by the Delaware General Corporation Law. 

(b) Subsection 2.2(b) of the Disclosure Schedule sets forth the capitalization of the Company immediately following the Initial Closing
including the number of shares of the following: (i) issued and outstanding Common Stock, including, with respect to restricted Common Stock, vesting schedule and repurchase price; (ii) granted stock options, including vesting schedule and
exercise price; (iii) shares of Common Stock reserved for future award grants under the Stock Plan; (iv) each series of Preferred Stock; and (v) warrants or stock purchase rights, if any. Except for (A) the conversion privileges
of the Shares to be issued under this Agreement, and (B) the rights provided in Section 4 of the Investors’ Rights Agreement, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of
first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares of Common Stock or Series A Preferred Stock, or any securities convertible into or exchangeable for shares of Common Stock or
Series A Preferred Stock. All outstanding shares of the Company’s Common Stock and all shares of the Company’s Common Stock underlying outstanding options are subject to (i) a right of first refusal in favor of the Company upon any
proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up or market standoff agreement of not less than one hundred eighty (180) days following the Company’s
initial public offering pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act. 

  
 4 













 (c) None of the Company’s stock purchase agreements or stock option documents contains
a provision for acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding upon the occurrence of any event or combination of events, including without
limitation in the case where the Company’s Stock Plan is not assumed in an acquisition. The Company has never adjusted or amended the exercise price of any stock options previously awarded, whether through amendment, cancellation, replacement
grant, repricing, or any other means. Except as set forth in the Restated Certificate, the Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital stock. 

(d) The Company has obtained valid waivers of any rights by other parties to purchase any of the Shares covered by this Agreement. 

2.3 Subsidiaries. The Company does not currently own or control, directly or indirectly, any interest in any other corporation,
partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or similar arrangement. 

2.4 Authorization. All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to
authorize the Company to enter into the Transaction Agreements, and to issue the Shares at the Closing and the Common Stock issuable upon conversion of the Shares, has been taken or will be taken prior to the Closing. All action on the part of the
officers of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of the Company under the Transaction Agreements to be performed as of the Closing, and the issuance and delivery of
the Shares has been taken or will be taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in
accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the
Investors’ Rights Agreement and the Indemnification Agreement may be limited by applicable federal or state securities laws. 
 2.5
Valid Issuance of Shares. The Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on
transfer other than restrictions on transfer under the Transaction Agreements, applicable state and federal securities laws and liens or encumbrances created by or imposed by a Purchaser. Assuming the accuracy of the representations of the Purchaser
in Section 3 of this Agreement and subject to the filings described in the Voting Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws. The Common Stock issuable upon conversion of the Shares
has been duly 

  
 5 













 
reserved for issuance, and upon issuance in accordance with the terms of the Restated Certificate, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other
than restrictions on transfer under the Transaction Agreements, applicable federal and state securities laws and liens or encumbrances created by or imposed by a Purchaser. Based in part upon the representations of the Purchaser in Section 3 of
this Agreement and in the Voting Agreement, the Common Stock issuable upon conversion of the Shares will be issued in compliance with all applicable federal and state securities laws. 

2.6 Governmental Consents and Filings. Assuming the accuracy of the representations made by the Purchaser in
Section 3 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the
part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for (i) the filing of the Restated Certificate, which will have been filed as of the Initial Closing, and (ii) filings
pursuant to Regulation D of the Securities Act, to the extent the Company has relied on Rule 506 of Regulation D, and applicable state securities laws, which have been made or will be made in a timely manner. 

2.7 Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to the
Company’s knowledge, currently threatened (i) against the Company or, to the Company’s knowledge, any officer, director of the Company, or any manager, officer or member of Founder (including any Founder Member); or (ii) that
questions the validity of the Transaction Agreements or the right of the Company to enter into them, or to consummate the transactions contemplated by the Transaction Agreements; or (iii) to the Company’s knowledge, that would reasonably
be expected to have, either individually or in the aggregate, a Material Adverse Effect. Neither the Company nor, to the Company’s knowledge, any of its officers, directors or Founders is a party or is named as subject to the provisions of any
order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or Founders, such as would affect the Company) that would reasonably be expected to have a Material Adverse Effect.
There is no action, suit, proceeding or investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any
basis therefor known to the Company) involving the prior employment of any of the Company’s employees, their services provided in connection with the Company’s business, any information or techniques allegedly proprietary to any of their
former employers or their obligations under any agreements with prior employers. 
 2.8 Intellectual Property. The Company owns or
possesses or can acquire on commercially reasonable terms sufficient legal rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others, including prior employees or consultants, or academic
or medical institutions with which any of them may be affiliated now or may have been affiliated in the past. No product or product candidate marketed or sold (or proposed to be marketed or sold) by the Company violates or will violate any license
or infringes or will infringe any intellectual property rights of any other party. Other than with respect to commercially available software products under standard end- user object code license agreements,
there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company Intellectual Property, nor is the 

  
 6 













 
Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses,
information, proprietary rights and processes of any other Person. The Company has not received any communications alleging that the Company has violated, or by conducting its business, would violate any of the patents, trademarks, service marks,
tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person. The Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other
software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the Company’s business. It will not be necessary to use any inventions of any of its employees or
consultants (or Persons it currently intends to hire) made prior to their employment by the Company, including prior employees or consultants, or academic or medical institutions with which any of them may be affiliated now or may have been
affiliated in the past. Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related to the Company’s business as now conducted and as presently proposed to be conducted and all
intellectual property rights that he, she or it solely or jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship with the Company that (a) relate, at the time of
conception, reduction to practice, development, or making of such intellectual property right, to the Company’s business as then conducted or as then proposed to be conducted, (b) were developed on any amount of the Company’s time or
with the use of any of the Company’s equipment, supplies, facilities or information or (c) resulted from the performance of services for the Company. Subsection 2.8 of the Disclosure Schedule lists all patents, patent applications,
trademarks, trademark applications, service marks, service mark applications, tradenames, copyrights, and licenses to and under any of the foregoing, in each case owned by the Company. The Company has not embedded any open source, copyleft or
community source code in any of its products generally available or in development, including but not limited to any libraries or code licensed under any General Public License, Lesser General Public License or similar license arrangement. For
purposes of this Subsection 2.8, the Company shall be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right or would be found to be on notice of such patent right as determined by reference to United
States patent laws. No government funding, facilities of a university, college, other educational institution or research center, or funding from third parties was used in the development of any Company Intellectual Property. No Person who was
involved in, or who contributed to, the creation or development of any Company Intellectual Property, has performed services for the government, university, college, or other educational institution or research center in a manner that would affect
Company’s rights in the Company Intellectual Property. 
 2.9 Compliance with Other Instruments. The Company is not in violation
or default of any provisions of its Restated Certificate or Bylaws, and is not in violation or default the violation of or default of which would have a Material Adverse Effect: (a) of any instrument, judgment, order, writ or decree,
(b) under any note, indenture or mortgage, or (c) under any lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule, or (d) of any provision
of federal or state statute, rule or regulation applicable to the Company. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in
any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement; or (ii) an
event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company. 

  
 7 













 2.10 Agreements; Actions. 

(a) Except for the Transaction Agreements and except as disclosed in Subsection 2.10(a) of the Disclosure Schedule, there are no agreements,
understandings, instruments, contracts or proposed transactions to which the Company is a party or by which it is bound that involve (i) obligations (contingent or otherwise) of, or payments to, the Company in excess of $100,000, (ii) the
license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company, (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that limit the
Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (iv) indemnification by the Company with respect to infringements of proprietary rights. 

(b) Except as disclosed in Subsection 2.10(b) of the Disclosure Schedule the Company has not (i) declared or paid any dividends, or
authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $100,000 or in excess of $50,000
in the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the
ordinary course of business. For the purposes of (a) and (b) of this Subsection 2.10, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person (including
Persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsection. 

(c) The Company is not a guarantor or indemnitor of any indebtedness of any other Person. 

2.11 Certain Transactions. 

(a) Other than (i) standard employee benefits generally made available to all employees, (ii) standard director and officer
indemnification agreements approved by the Board of Directors, and (iii) the purchase of shares of the Company’s capital stock and the issuance of options to purchase shares of the Company’s Common Stock, in each instance, approved in
the written minutes of the Board of Directors (previously provided to the Purchaser or its counsel), and other than the grant of certain securities to the Company’s Chief Medical Officer, there are no agreements, understandings or proposed
transactions between the Company and any of its officers, directors, consultants or the Founder or any Founder Member, or any Affiliate thereof. 

(b) The Company is not indebted, directly or indirectly, to any of its directors, officers or employees or to their respective spouses or
children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally
available to all employees. None of the Company’s directors, officers or 

  
 8 













 
employees, or any members of their immediate families, or any Affiliate of the foregoing are, directly or indirectly, indebted to the Company or, to the Company’s knowledge, have any
(i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of the Company’s customers, suppliers, service providers, joint venture partners, licensees and competitors,
(ii) direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation which competes with the Company except that directors,
officers, employees or stockholders of the Company may own stock in (but not exceeding two percent (2%) of the outstanding capital stock of) publicly traded companies that may compete with the Company; or (iii) financial interest in any
contract with the Company. 
 2.12 Rights of Registration and Voting Rights. Except as provided in the Investors’ Rights
Agreement, the Company is not under any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. To the Company’s
knowledge, except as contemplated in the Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company. 

2.13 Property. The property and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens, loans and
encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such
property or assets. With respect to the property and assets it leases, the Company is in compliance with such leases and holds a valid leasehold interest free of any liens, claims or encumbrances other than those of the lessors of such property or
assets. The Company does not own any real property. 
 2.14 Material Liabilities. The Company has no liability or obligation, absolute
or contingent (individually or in the aggregate), except (i) obligations and liabilities incurred after the date of incorporation in the ordinary course of business that are not material, individually or in the aggregate, and
(ii) obligations under contracts made in the ordinary course of business that would not be required to be reflected in financial statements prepared in accordance with GAAP. 

2.15 Employee Matters. 

(a) As of the date hereof, the Company employs four (4) full-time employees and no part-time employees and engages no consultants or
independent contractors. Subsection 2.15 of the Disclosure Schedule sets forth a detailed description of all compensation, including salary, bonus, severance obligations and deferred compensation paid or payable for each officer, employee,
consultant and independent contractor of the Company. 
 (b) None of the Company’s employees is obligated under any contract (including
licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of the
Company or that would conflict with the Company’s business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the
Company’s business as now conducted and as presently proposed to be conducted, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract,
covenant or instrument under which any such employee is now obligated. 

  
 9 













 (c) The Company is not delinquent in payments to any of its employees, consultants, or
independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or independent contractors.
The Company has complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification and collective
bargaining. The Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of the Company and is not liable for any
arrears of wages, taxes, penalties or other sums for failure to comply with any of the foregoing. 
 (d) To the Company’s knowledge, no
Founder Member who is an employee or consultant of the Company intends to terminate such employment or consulting relationship with the Company or is otherwise likely to become unavailable to continue in his correct role. The employment of each
employee of the Company is terminable at the will of the Company. Except as set forth in Subsection 2.15 of the Disclosure Schedule or as required by law, upon termination of the employment of any such employees, no severance or other payments will
become due. Except as set forth in Subsection 2.15 of the Disclosure Schedule, the Company has no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination of employment
services. 
 (e) The Company has not made any representations regarding equity incentives to any officer, employee, director or consultant
that are inconsistent with the share amounts and terms set forth in the minutes of meetings of the Company’s Board of Directors. 
 (f)
Each former employee of the Company whose employment was terminated by the Company has entered into an agreement with the Company providing for the full release of any claims against the Company or any related party arising out of such employment.

 (g) Subsection 2.15 of the Disclosure Schedule sets forth each employee benefit plan maintained, established or sponsored by the Company,
or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The Company has made all required contributions and has no liability to any such
employee benefit plan, other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA, and has complied in all material respects with all applicable laws for any such employee benefit plan. 

(h) To the Company’s knowledge, none of the Founder Members or directors of the Company has been (a) subject to voluntary or
involuntary petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer by a court for his or her business or property; (b) convicted in a criminal proceeding or named
as a subject of a pending criminal proceeding (excluding traffic violations and other minor 

  
 10 













 
offenses); (c) subject to any order, judgment or decree (not subsequently reversed, suspended, or vacated) of any court of competent jurisdiction permanently or temporarily enjoining him or her
from engaging, or otherwise imposing limits or conditions on his or her engagement in any securities, investment advisory, banking, insurance, or other type of business or acting as an officer or director of a public company; or (d) found by a
court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any federal or state securities, commodities, or unfair trade practices law, which such
judgment or finding has not been subsequently reversed, suspended, or vacated. 
 2.16 Tax Returns and Payments. There are no federal,
state, county, local or foreign taxes due and payable by the Company which have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company which are due, whether or not assessed or disputed.
There have been no examinations or audits of any tax returns or reports by any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state, county, local and foreign tax returns required
to have been filed by it and there are in effect no waivers of applicable statutes of limitations with respect to taxes for any year. 
 2.17
Insurance. The Company has in full force and effect insurance policies concerning such casualties as would be reasonable and customary for companies like the Company. 

2.18 Employee Agreements. Each current and former employee, consultant and officer of the Company has executed an agreement with the
Company regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for the Purchaser (the “Confidential Information Agreements”). No current or former employee of the Company
has excluded works or inventions from his or her assignment of inventions pursuant to such employee’s Confidential Information Agreement. The Company is not aware that any of the Founder Members or any Company employees is in violation of any
agreement covered by this Subsection 2.18. 
 2.19 Permits. The Company has all franchises, permits, licenses and any similar
authority necessary for the conduct of its business, the lack of which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any material respect under any of such franchises, permits, licenses or other
similar authority. 
 2.20 Corporate Documents. The Restated Certificate and Bylaws of the Company are in the form provided to the
Purchaser. The copy of the minute books of the Company provided to the Purchaser contains minutes of all meetings of directors and stockholders and all actions by written consent without a meeting by the directors and stockholders since the date of
incorporation and accurately reflects in all material respects all actions by the directors (and any committee of directors) and stockholders with respect to all transactions referred to in such minutes. 

  
 11 













 2.21 Qualified Small Business Stock. As of and immediately following the Closing:
(i) the Company will be an eligible corporation as defined in Section 1202(e)(4) of the Code, (ii) the Company will not have made purchases of its own stock described in Code Section 1202(c)(3)(B) during the one (1) year
period preceding the Initial Closing, except for purchases that are disregarded for such purposes under Treasury Regulation Section 1.1202-2, and (iii) the Company’s aggregate gross assets, as
defined by Code Section 1202(d)(2), at no time between its incorporation and through the Initial Closing have exceeded $50 million, taking into account the assets of any corporations required to be aggregated with the Company in accordance
with Code Section 1202(d)(3); provided, however, that in no event shall the Company be liable to the Purchaser or any other party for any damages arising from any subsequently proven or identified error in the Company’s determination with
respect to the applicability or interpretation of Code Section 1202, unless such determination shall have been given by the Company in a manner either grossly negligent or fraudulent. 

2.22 Disclosure. The Company has made available to the Purchaser all the information reasonably available to the Company that the
Purchaser have requested for deciding whether to acquire the Shares, including certain of the Company’s projections describing its proposed business plan (the “Business Plan”). No representation or warranty of the Company
contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Purchaser at the Closing contains any untrue statement of a material fact or omits to state a material fact necessary in order
to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. The Business Plan was prepared in good faith; however, the Company does not warrant that it will achieve any results
projected in the Business Plan. It is understood that this representation is qualified by the fact that the Company has not delivered to the Purchaser, and has not been requested to deliver, a private placement or similar memorandum or any written
disclosure of the types of information customarily furnished to purchasers of securities. 
 2.23 Foreign Corrupt Practices Act.
Neither the Company nor any of its directors, officers or employees have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official”
(as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any
official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any
improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor any of its
directors, officers or employees have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. Neither the Company
nor, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law
(collectively, “Enforcement Action”). 

  
 12 













 2.24 Preclinical Development. The studies, tests and preclinical development and
clinical trials, if any, conducted by or on behalf of the Company are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional and scientific standards for products
or product candidates comparable to those being developed by the Company and all applicable laws and regulations, including the Federal Food, Drug, and Cosmetic Act and 21 C.F.R. parts 50, 54, 56, 58, 312, and 812. The descriptions of, protocols
for, and data and other results of, the studies, tests, development and trials conducted by or on behalf of the Company that have been furnished or made available to the Purchaser are accurate and complete. The Company is not aware of any studies,
tests, development or trials the results of which reasonably call into question the results of the studies, tests, and the proposed development conducted by or on behalf of the Company, and the Company has not received any notices or correspondence
from the FDA or any other Governmental Entity or any Institutional Review Board or comparable authority requiring the termination, suspension or material modification of any studies, tests, preclinical development or clinical trials conducted by or
on behalf of the Company. 
 3. Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the
Company, severally and not jointly, that: 
 3.1 Authorization. The Purchaser has full power and authority to enter into the
Transaction Agreements. The Transaction Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser, enforceable in accordance with their terms,
except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Investors’ Rights Agreement may be limited by applicable federal or state
securities laws. 
 3.2 Purchase Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the
Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing
this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with
respect to any of the Shares. The Purchaser has not been formed for the specific purpose of acquiring the Shares. 
 3.3 Disclosure of
Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an opportunity to
review the Company’s facilities. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Purchaser to rely thereon. 

  
 13 













 3.4 Restricted Securities. The Purchaser understands that the Shares have not been,
and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of
the Purchaser’s representations as expressed herein. The Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must
hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges
that the Company has no obligation to register or qualify the Shares, or the Common Stock into which it may be converted, for resale except as set forth in the Investors’ Rights Agreement. The Purchaser further acknowledges that if an exemption
from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company which are
outside of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. 
 3.5 No Public
Market. The Purchaser understands that no public market now exists for the Shares, and that the Company has made no assurances that a public market will ever exist for the Shares. 

3.6 Legends. The Purchaser understands that the Shares and any securities issued in respect of or exchange for the Shares, may be
notated with one or all of the following legends: 
 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE
BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 
 (a) Any legend set forth in,
or required by, the other Transaction Agreements. 
 (b) Any legend required by the securities laws of any state to the extent such laws are
applicable to the Shares represented by the certificate, instrument, or book entry so legended. 
 3.7 Accredited Investor. The
Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

  
 14 













 3.8 Foreign Investors. If the Purchaser is not a United States person (as defined by
Section 7701(a)(30) of the Code), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement,
including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained,
and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser’s subscription and payment for and continued beneficial ownership of the
Shares will not violate any applicable securities or other laws of the Purchaser’s jurisdiction. 
 3.9 No General Solicitation.
Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any
advertisement in connection with the offer and sale of the Shares. 
 3.10 Exculpation Among Purchaser. The Purchaser acknowledges
that it is not relying upon any Person, other than the Company, in making its investment or decision to invest in the Company. The Purchaser agrees that neither the Purchaser nor the respective controlling Persons, officers, directors, partners,
agents, or employees of the Purchaser shall be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Shares. 

3.11 Residence. If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the address of the
Purchaser set forth on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address or
addresses of the Purchaser set forth on Exhibit A. 
 4. Conditions to the Purchaser’s Obligations at each
Closing. The obligations of the Purchaser to purchase Shares at the Initial Closing or any Milestone Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived: 

4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and
correct in all respects as of such Closing. 
 4.2 Performance. The Company shall have performed and complied with all covenants,
agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Company on or before such Closing. 

4.3 Compliance Certificate. The President of the Company shall deliver to the Purchaser at such Closing a certificate certifying that
the conditions specified in Subsections 4.1 and 4.2 have been fulfilled. 
 4.4 Qualifications. All authorizations, approvals or
permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be obtained and effective as of
such Closing. 

  
 15 













 4.5 Opinion of Company Counsel. The Purchaser shall have received from Mayer Brown
LLP, counsel for the Company, an opinion, dated as of the Initial Closing, in substantially the form of Exhibit H attached to this Agreement. 

4.6 Indemnification Agreement. The Company shall have executed and delivered the Indemnification Agreements. 

4.7 Investors’ Rights Agreement. The Company and the Purchaser (other than the Purchaser relying upon this condition
to excuse the Purchaser’s performance hereunder) and the other stockholders of the Company named as parties thereto shall have executed and delivered the Investors’ Rights Agreement. 

4.8 Right of First Refusal and Co-Sale Agreement. The Company, the Purchaser (other than the
Purchaser relying upon this condition to excuse the Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto shall have executed and delivered the Right of First Refusal and Co-Sale Agreement. 
 4.9 Voting Agreement. The Company, the Purchaser (other than the Purchaser
relying upon this condition to excuse the Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto shall have executed and delivered the Voting Agreement. 

4.10 Employment Agreement. The Company and each Founder Member shall have executed and delivered an employment agreement for such in
such form as has been agreed between the Company, such Founder Member and the Purchaser. 
 4.11 Restated Certificate. The Company
shall have filed the Restated Certificate with the Secretary of State of Delaware on or prior to the Closing, which shall continue to be in full force and effect as of the Closing. 

4.12 D&O Insurance. The Company shall have obtained director and officers insurance from a reputable insurer in such amounts and as
otherwise customary for a company engaged in a similar business as the Company and at a comparable stage of development to the Company all of which shall be reasonably satisfactory to the Board of Directors. 

4.13 Secretary’s Certificate. The Secretary of the Company shall have delivered to the Purchaser at the Closing a
certificate certifying (i) the bylaws of the Company, and (ii) the joint resolutions of the Board of Directors of the Company approving the Transaction Agreements and the transactions contemplated under the Transaction Agreements and the
sole stockholder of the Company approving the Restated Certificate. 
 4.14 Proceedings and Documents. All corporate and other
proceedings in connection with the transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to the Purchaser, and the Purchaser (or its counsel) shall have received all such
counterpart original and certified or other copies of such documents as reasonably requested. Such documents may include good standing certificates. 

  
 16 













 4.15 Post-Closing Covenants. In connection with the Closing, the Company shall
establish a stock option plan not exceeding [***]% of the Company’s equity on a fully diluted basis, on such terms and conditions as the Board of Directors of the Company shall approve, provided, however, that it is understood that (unless
otherwise agreed by the Board of Directors) the Founder Members shall not receive additional options or other equity securities in the Company and (ii) the shares of common stock of the Company held by any optionee will be non-voting. 
 5. Conditions of the Company’s Obligations at each Closing. The
obligations of the Company to sell Shares to the Purchaser at the Initial Closing or any Milestone Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived: 

5.1 Representations and Warranties. The representations and warranties of the Purchaser contained in Section 3 shall be true and
correct in all respects as of such Closing. 
 5.2 Performance. The Purchaser shall have performed and complied with all covenants,
agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by them on or before such Closing. 

5.3 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United
States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be obtained and effective as of the Closing. 

6. Miscellaneous. 
 6.1
Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchaser contained in or made pursuant to this Agreement shall survive for two years following the execution and
delivery of this Agreement and the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchaser or the Company. 

6.2 Successors and Assigns. This Agreement, and the rights and obligations of the Purchaser hereunder, may be assigned by the Purchaser
only to an Affiliate of the Purchaser, and, in such case, such transferee shall be deemed a “Purchaser” for purposes of this Agreement; provided that each such assignment of rights shall be contingent upon the transferee providing a
written instrument to the Company notifying the Company of such transfer and assignment and agreeing in writing to be bound by the terms of this Agreement. The Company may not assign its rights under this Agreement. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in
this Agreement. 
 6.3 Governing Law. This Agreement shall be governed by the internal law of the State of New York, without regard to
conflict of law principles that would result in the application of any law other than the law of the State of New York. 

  
 17 













 6.4 Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.6 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during normal business hours of the
recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1)
business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as
set forth on the signature page or Exhibit A, or to such e-mail address or address as subsequently modified by written notice given in accordance with this Subsection 6.6. If notice is given to the Company, a
copy shall also be sent to Anna T. Pinedo, Mayer Brown LLP at apinedo@mayerbrown.com and if notice is given to the Purchaser, a copy shall also be given to Kristina Beirne, Dentons US LLP at kristina.beirne@dentons.com. 

6.7 No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or
commission in connection with this transaction. The Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this
transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Purchaser or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless the
Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which
the Company or any of its officers, employees or representatives is responsible. 
 6.8 Fees and Expenses. At the Closing, the Company
shall pay the reasonable fees and expenses of Dentons US LLP, the counsel for Purchaser, in an amount not to exceed, in the aggregate, $75,000. 

6.9 Attorneys’ Fees. If any action at law or in equity (including arbitration) is necessary to enforce or interpret
the terms of any of the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

6.10 Amendments and Waivers. Except as set forth in Subsection 1.3(a) of this Agreement, any term of this Agreement may be amended,
terminated or waived only with the written consent of the Company and the holders of at least a majority of the then-outstanding shares of Series A Preferred Stock. Any amendment or waiver effected in accordance with this Subsection 6.10 shall be
binding upon the Purchaser and each transferee of the Shares (or the Common Stock issuable upon conversion thereof), each future holder of all such securities, and the Company. 

  
 18 













 6.11 Severability. The invalidity or unenforceability of any provision hereof shall
in no way affect the validity or enforceability of any other provision. 
 6.12 Delays or Omissions. No delay or omission to exercise
any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement,
or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or
otherwise afforded to any party, shall be cumulative and not alternative. 
 6.13 Entire Agreement. This Agreement (including the
Exhibits hereto), the Restated Certificate and the other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement
relating to the subject matter hereof existing between the parties are expressly canceled. 
 6.14 Termination of Closing Obligations.
The Purchaser shall have the right to terminate its obligations to complete any Milestone Closing, as the case may be, if prior to the occurrence thereof, any of the following occurs: 

(a) the Company consummates a Deemed Liquidation Event (as defined in the Restated Certificate); or 

(b) the Company (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any
proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, or files a petition or answer seeking
reorganization or an arrangement with creditors to take advantage of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed against it, or (v) becomes subject to
any involuntary proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, when proceeding is not dismissed
within thirty (30) days of filing, or have an order for relief entered against it in any proceedings under the United States Bankruptcy Code. 

  
 19 













 6.15 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state and federal courts located in the State of New York for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other
proceeding arising out of or based upon this Agreement except in the state or federal courts located in the State of New York, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action
or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum,
that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE
OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL- ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT
RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH
OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL 
 6.16 No Commitment for Additional Financing. The Company
acknowledges and agrees that no Purchaser has made any representation, undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance, other than the purchase of the Shares as set
forth herein and subject to the conditions set forth herein and cooperation in connection with the Company’s proposed initial public offering (“IPO”) as described in the Transaction Documents. In addition, the Company acknowledges and
agrees that (i) no statements, whether written or oral, made by the Purchaser or its representatives on or after the date of this Agreement shall create an obligation, commitment or agreement to provide or assist the Company in obtaining any
financing or investment, (ii) the Company shall not rely on any such statement by the Purchaser or its representatives, and (iii) an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or
investment may only be created by a written agreement, signed by the Purchaser and the Company, setting forth the terms and conditions of such financing or investment and stating that the parties intend for such writing to be a binding obligation or
agreement. The Purchaser shall have the right, in its sole and absolute discretion, to refuse or decline to participate in any other financing of or investment in the Company, and shall have no obligation, other than in connection with the IPO, to
assist or cooperate with the Company in obtaining any financing, investment or other assistance. 

  
 20 













 6.17 No Further Issuances. Until all the Milestones have been achieved, other than as
approved by the Board of Directors of the Company (including the affirmative vote of at least two (2) of the directors nominated by the Purchaser), the Company will not (i) issue any additional capital stock or other equity securities of
the Company (including securities convertible into or exchangeable for such equity securities) other than the Preferred Stock issued at any Milestone Closing, or (ii) take uncoordinated action to solicit, initiate, encourage or assist the
submission of any proposal, negotiation or offer from any person or entity other than the Purchaser relating to the sale or issuance, of any of the capital stock of the Company or the acquisition, sale, lease, license or other disposition of the
Company or any material part of the stock or assets of the Company and shall notify the Purchaser promptly of any inquiries by any third parties in regards to the foregoing. 

  
 21 













 IN WITNESS WHEREOF, the parties have executed this Preferred Stock Purchase Agreement as of
the date first written above. 
  

			
	COMPANY
	
	GABA THERAPEUTICS, INC.:
		
	By:	 	     /s/ Richard Farrell

	
	Name: Richard Farrell
	
	Title: Vice President and Treasurer


 
			
		
	Address:	 	5000 Birch Street, West Tower,
		
		 	Suite 3000 Newport Beach, CA 92660


 [Signature page to preferred Stock Purchase Agreement] 

  













 
			
	PURCHASER 
	
	 ATAI LIFE SCIENCES AG

		
	By:	 	     /s/ Florian Brand

	
	 Name: Florian Brand

	
	 Title: Vorstand (Chief Executive Officer)





			
		
	Address:	 	 Barer Str. 7, 80333 Munich, Germany 



 [Signature page to preferred Stock Purchase Agreement] 

  













 OMNIBUS AMENDMENT 

THIS OMNIBUS AMENDMENT (this “Amendment”) is entered into as of October 30, 2020, by and among ATAI LIFE SCIENCES AG, a
German corporation (“ATAI”), GABA THERAPEUTICS, LLC, a Delaware limited liability company (“Founder” and referred to together with ATAI, as “Shareholders”), and GABA THERAPEUTICS, INC., a Delaware
corporation (the “Company”). 
 W I T N E S S E T H: 

A. The Shareholders and the Company have entered into (i) that certain PREFERRED STOCK PURCHASE AGREEMENT (the “SPA”),
(ii) that certain RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “ROFR Agreement”), (iii) that certain INVESTORS’ RIGHTS AGREEMENT (the “IRA”), and (iv) that
certain VOTING AGREEMENT (the “VA”), each dated as of August 29, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, collectively, the “Agreements”). 

B. Pursuant to Section 6.17 of the SPA, other than as permitted by such clause, the Company has agreed to refrain from issuances of
additional equity securities, and from taking certain actions relating to the sale or issuance of any of the capital stock, of the Company or the acquisition, sale, lease, license or other disposition of the Company or of a material part of the
stock or assets of the Company (as further set forth therein, the “No Further Issuances Clause”). 
 C. Pursuant to
Section 4.1 of the IRA, subject to the terms and conditions of such clause, the Company is required to first offer any New Securities (as defined therein) to ATAI as the Investor (as defined in the IRA) (as further set forth therein, the
“Preemptive Rights Clause”). 
 D. The Shareholders and the Company desire to amend or waive certain clauses of the
Agreements, [***], subject to the terms and conditions (including conditions to effectiveness) set forth below. 
 NOW, THEREFORE, in
consideration of the mutual agreements, provisions and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

SECTION 1. Defined Terms. Capitalized terms used herein (including in the preamble and recitals above) but not otherwise
defined herein shall have the respective meanings ascribed to such terms in the SPA. 
 SECTION 2. Amendments to ROFR
Agreement. The parties hereby agree that the ROFR Agreement shall be amended as set forth below: 
 (a) Section
2.4(a) of the ROFR Agreement shall hereby be amended by deleting it in its entirety and replacing it with the following: 

  
 1 













 “(a) Grant. Upon one (1) day prior written notice, but in
any event on or before November 6, 2020 (the “Call Option Termination Date”), Founder hereby unconditionally and irrevocably grants to Investor the right to purchase [***] shares of Common Stock then held by Founder at the
price and subject to the conditions set forth in this Section 2.4 (the “Call Option”). For purposes of this Section 2.4, “Investor” shall refer solely to ATAI Life
Sciences AG and its permitted successors and assigns or any direct or indirect parent entity thereof. For clarity, the total cost of Investor’s potential exercise of the Call Option hereunder is limited to the Call Option price set forth in
Section 2.4, and no other amounts (including, without limitation, any Milestone Payments) will be due or owing for any such exercise. Any amounts owing pursuant to this Section 2.4(a) will be paid to Founder by such Investor within thirty
(30) days of its exercise of the Call Option.” 
 (b) Section 2.4(c) of the ROFR Agreement shall hereby be amended
by deleting it in its entirety and replacing it with the following: 
 “(c) Call Option Price. The purchase price
per share for the shares subject to the Call Option shall be $[***] per share.” 
 SECTION 3. Amendments to VA.
The parties hereby agree that the VA shall be amended as set forth below: 
 (a) Section 1.2(b) of the VA shall hereby be
amended by deleting it in its entirety and replacing it with the following: 
 “(b)(i) One person designated from time
to time by the Founder (excluding, for these purposes, the Anvyl Partners (as defined below)), which individual shall initially be Richard Farrell as of November 6, 2020, and one person designated from time to time by the original discoverers
of both S- etifoxine and deuterated etifoxine (the “Anvyl Partners”), which individual shall initially be Ian Massey as of November 6, 2020, in both cases only for so long as the Founder and its
Affiliates (as defined below) continue to own beneficially at least 50% of the shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any Preferred Stock) held by them at the Initial Closing; and 

(ii) The Founder hereby agrees that it will not coordinate with any of the Anvyl Partners with respect to any rights or
obligations under this Agreement, the Agreements, or otherwise enter into any voting agreement, buy/sell or any other arrangement, which shall modify the Founders’ or the Anvyl Partners’ rights under this Agreement; and” 

SECTION 4. Amendments to the IRA. The parties hereby agree that the IRA shall be amended as set forth below: 

(a) Section 4.1(b) of the IRA shall hereby be amended by deleting it in its entirety and replacing it with the following: 

  
 2 













 “(b) By notification to the Company within twenty (20) days after
the Offer Notice is given, each Investor may elect to purchase, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor
(including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of
the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the
later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).” 

SECTION 5. Forbearance/Amendment of No Further Issuances Clause. Commencing immediately following ATAI’s (or any
successor entity’s or any direct or indirect parent entity thereof) initial public offering of its capital stock (or other transaction that has the effect of resulting in the listing of ATAI’s (or such successor entity’s or any direct
or indirect parent entity thereof) equity securities on a national or international securities exchange), [***], ATAI shall support the Company’s growth and development by (i) not exercising the No Further Issuances Clause in order to, and
to the extent reasonably necessary to, [***], and (ii) not purchase the Milestone Shares attributable to Milestone 2 absent receipt of the certification by the Board that Milestone 2 has occurred; provided, however, that ATAI may exercise its
right to purchase such Milestone Shares, upon written notice to the Company, immediately preceding (a) any BOD approved sale or acquisition of the Company or of substantially all of the stock or assets of the Company (including by way of an
option or license), or (b) the Company entering any agreement to do any of the foregoing; provided, that, in the case of an option or license agreement for which a material portion of the economic benefit to the Company is contingent upon
future conditions, [***.] 
 SECTION 6. Further Assurances. Each of the parties hereto agrees to execute, acknowledge,
seal and deliver, after the date hereof, without additional consideration, such further assurances, instruments and documents, and to take such further actions, as another party may reasonably request in order to fulfill the intent of this agreement
and the transactions contemplated hereby. 
 SECTION 7. Counterparts. This Amendment may be executed in any number of
counterparts and by the different parties hereto on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Amendment. Receipt by facsimile or other
electronic transmission (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.hellosign.com) of any executed signature page to this Amendment shall constitute effective delivery of such signature
page. 
 SECTION 8. Agreements. Other than as specifically set forth herein, the Agreements shall remain in full force
and effect. 

  
 3 













 SECTION 9. Miscellaneous. Sections 6.2, 6.3, 6.5 through 6.13 and 6.15
of the SPA (or any successor provisions thereto) shall apply to this Amendment mutatis mutandis. 
 [Signature Pages Follow]


  
 4 













 Each of the undersigned has caused the Amendment to be duly executed and delivered as of the
date first above written. 
  

			
	GABA THERAPEUTICS, INC.
		
	By:	 	
                     
    

	Name:
	Title:
	
	ATAI LIFE SCIENCES AG
		
	By:	 	
                     
    

	Name:
	Title:
	
	GABA THERAPEUTICS, LLC
		
	By:	 	
                     
                    

	Name:
	Title:



  
 5